Edition:
United Kingdom

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

2.84USD
13 Jul 2018
Change (% chg)

$-0.04 (-1.39%)
Prev Close
$2.88
Open
$2.88
Day's High
$2.95
Day's Low
$2.84
Volume
35,512
Avg. Vol
85,941
52-wk High
$4.09
52-wk Low
$1.17

Chart for

About

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response... (more)

Overall

Beta: --
Market Cap(Mil.): $100.36
Shares Outstanding(Mil.): 52.27
Dividend: --
Yield (%): --

Financials

  SRRA.OQ Industry Sector
P/E (TTM): -- 85.48 32.76
EPS (TTM): -1.26 -- --
ROI: -38.70 2.29 14.61
ROE: -38.70 3.86 16.34

BRIEF-Sierra Oncology Reports Qtrly Loss Per Share $0.19

* SIERRA ONCOLOGY INC - SRA737 MONOTHERAPY PHASE 1/2 TRIAL EXPANDED TO ENROLL CCNE1-DRIVEN OVARIAN CANCER COHORT

10 May 2018

BRIEF-Sierra Oncology Announces Pricing Of Public Offering Of Common Stock

* SIERRA ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

02 Mar 2018

BRIEF-Sierra Oncology Announces Proposed Public Offering Of Common Stock

* SIERRA ONCOLOGY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

01 Mar 2018

BRIEF-Sierra Oncology Significantly Expands Clinical Development Program

* SIERRA ONCOLOGY SIGNIFICANTLY EXPANDS CLINICAL DEVELOPMENT PROGRAM

27 Feb 2018

BRIEF-Sierra Oncology Reports Qtrly Loss Of $0.20 Per Share

* SIERRA ONCOLOGY INC - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.20‍​

27 Feb 2018

Earnings vs. Estimates